Trastuzumab emtansine in breast cancer

Bibliography

• Schechter AL, Stern DF, Vaidyanathan L, The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-16
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, Molecular portraits of human breast tumours. Nature 2000;406:747-52
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74
   PubMed Web of Science ®Google Scholar
• Seshadri R, Firgaira FA, Horsfall DJ, Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42
   PubMed Web of Science ®Google Scholar
• Sjogren S, Inganas M, Lindgren A, Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-9
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Valero V, Ibrahim NK, Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowsky T, Im Y-H, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim S-B, Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012;366:109-19
   PubMed Web of Science ®Google Scholar
• Teicher BA, Chari RVJ. Antibody conjugate Therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90
   PubMed Web of Science ®Google Scholar
• Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27(6 Suppl 11):21-5; discussion 92-100
   PubMed Web of Science ®Google Scholar
• Junutula JR, Flagelmla KM, Graham RA, Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16:4769-78
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li G, Parsons K, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56
   PubMed Web of Science ®Google Scholar
• Oroudjev E, Lopus M, Wilson L, Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010;9:2700-13
   Google Scholar
• Austin CD, Wen X, Gazzard L, Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA 2005;102:17987-92
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
   PubMed Web of Science ®Google Scholar
• Erickson HK, Philips GDL, Leipold DD, The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Res 2012;11:1133-42
   Google Scholar
• Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011;13:R46
   PubMed Web of Science ®Google Scholar
• Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011;306:171-9
   PubMed Web of Science ®Google Scholar
• Burris HA III, Rugo HS, Vukelja SJ, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405
   PubMed Web of Science ®Google Scholar
• Krop I, LoRusso P, Miller KD, A phase II study of trastuzumab emtansine in patients with human epidermal growth factor 2- positive metastatic breast cancer who were previously treated with tratuzumab, lapatinib, an anthracycline, a taxane and capecitabine. J Clin Oncol 2012;30:3234-41
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Weiss D, Guardino E, Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positiive cancer. Clin Cancer Res 2011;17:6437-47
   PubMed Web of Science ®Google Scholar
• Jumbe NL, Xin Y, Leipold DD, Modeling the efficacy of trastuzumab-DM1 an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 2010;37:221-42
   PubMed Web of Science ®Google Scholar
• Shen B-Q, Bumbaca D, Saad O, Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine: an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012;13:901-10
   PubMed Web of Science ®Google Scholar
• Girish S, Gupta M, Wang B, Clinical pharmacology of trastuzumab emtansine (T-DM1): a unique antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012;69:1229-40
   PubMed Web of Science ®Google Scholar
• Chudasama VL, Schaedeli Stark F, Harrold JM, Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012;92:520-7
   Web of Science ®Google Scholar
• Gupta M, LoRusso PM, Wang B, Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 2012;52:691-703
   PubMed Web of Science ®Google Scholar
• Lu D, Girish S, Gao Y, Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates. Cancer Res 2012;72(24 Suppl):457s; (#P5-18-24)
   Google Scholar
• Aogi K, Ando M, Iwata H, (2011) Phase I study of single agent trastuzumab emtansine in Japanese patients with human epidermal growth factor receptor2 (HER2)-positive metastatic breast cancer (JO22591). Cancer Res 2011;71(24 Suppl):16s; (# P1-12-19)
   Google Scholar
• Ito MN, Ito Y, Takao S, A multicenter Phase II study evaluating the efficacy and safety of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive metastatic breast cancer (JO22997). Cancer Res 2012;72(24 Suppl):472s; (# P5-18-16)
   PubMedGoogle Scholar
• Krop IE, Beeram M, Modi S, Phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
   PubMed Web of Science ®Google Scholar
• Beeram M, Krop IE, Burris HA, A phase I study of weekly dosing of trastuzumab Emtansin (T-DM1) in patients with advanced Human epidermal growth factor 2-positive breast cancer. Cancer 2012;118:5733-40
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Dirix L, Kocsis J, Trastuzumab Emtansine versus trastuzumab plus docetaxel for HER2-positive metastatic breast cancer. J Clin Oncology; In press
   Google Scholar
• Verma S, Miles D, Gianni L, Tratuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar
• Olson EM, Lin NU, DoPiro PJ, Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 2012;23:93-7
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Dirix L, Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced erbb2-positive breast cancer. J Clin Oncol 2010;1301-7
   PubMed Web of Science ®Google Scholar
• Bender BC, Schaedeli-Stark F, Koch R, A population pharmacokinetic/pharmacodynamics model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmavol 2012;70:591-601
   PubMed Web of Science ®Google Scholar
• Thon JN, Devine MT, Begonja AJ, High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012;120:1975-84
   PubMed Web of Science ®Google Scholar